Commentary regarding; Quantification of the Lamin A/C transcript variants in cancer cell lines by targeted absolute quantitative proteomics and correlation with mRNA expression

LMNA proteins are important in nuclear chromosomal stability and structural integrity. LMNA cumulative proteins expression of variants is done through Western blotting (semi-quantitative). To present day, there are not particular antibodies for individual laminA/C (LMNA) transcript variants. The mass spectrometric technique of quantifying laminA/C (LMNA) transcript variants has been developed and applied in the quantification. In the quantification, signature peptides for every particular laminA/C (LMNA) splice variant can be used. The LC-MS/MS assay technique based on targeted signature peptides as well as their internal standards (labeled) was identified in order to measure representation of LaminA/C (LMNA) transcript varied concentrations. Validation of the approach was conducted in accordance with the guidelines of Food and Drug Administration (FDA). The levels of expression for Lamin A/C (LMNA) transcript variations were examined in samples obtained from U937 and MCF7 cell lines. In addition, RT-qPCR assay approach was applied to compare and quantitate splice variants' mRNA expression for Lamin A/C (LMNA). The validated and established approach portrayed great precision, sensitivity, and linearity. The various expressed Lamin A/C (LMNA) variants in the various lines of cell were determined while their levels matched with the qRT-PCR results. The technique is reliable, sensitive, and reproducible in measuring Lamin A/C (LMNA) transcript variations in various cell lines.